Proliferation of circulating tumour cells for the personalised treatment of cancer patients

Cardiovascular diseases are the leading causes of death and disability worldwide. The identification of rare circulating endothelial cells (CECs) is a new, reliable biomarker associated with endothelial damage. From a clinical perspective, these endothelial cells are important indicators of pathological processes in the body and can therefore be used for the diagnosis and monitoring of various cardiovascular diseases. The aim of the project is therefore to develop a probe that enables the isolation of CECs in vivo directly from the patient’s blood, thereby circumventing the problem of ensuring a sufficient cell yield.